Academic Experience
2022 - 2024
Postdoctoral Fellow - Faculty of Law, University of Alberta
My research mapped and analysed regenerative medicine (RM) research activity and pipelines towards the clinical translation and market authorisation of regenerative medicine (RM) products and therapies, and associated trends and gaps in low and middle-income countries (LMICs). This research was validated at a workshop in South Africa that I co-organised which convened experts from diverse LMICs. I also researched the experiences of patients, clinicians, and researchers to understand ethical, legal, and societal issues related to regenerative medicine therapies in Canada.
2015 - 2022
Doctor of Philosophy - Psychiatry, McGill University
In response to the United Nations' Sustainable Development Goals and Decade of Action for Road Safety 2011-2020, I researched the role of alcohol in risky driving. While the per se criminal legal threshold for alcohol in Canada is 0.08% blood alcohol concentration (BAC), my research supports that a lower BAC of 0.05% may still result in greater risky driving among males, an at-risk group. I identified alcohol misuse as a significant predictor of risky driving as much as 3 years later among male first-time driving while impaired (DWI) offenders. I also sought to elucidate the neuropsychological (decision-making) and personality trait (sensation-seeking) effects of depressed mood and alcohol use/misuse on risky driving. Implications of my research include additional support for lowering the per se criminal legal threshold in Canada and the development of more targeted driver relicensing policies for DWI offenders. This research was supported by two grants from the Canadian Institutes of Health Research.
2013 - 2015
Master of Science - Medical Science, University of Calgary
My research identified the neuropsychological profile of cerebral amyloid angiopathy (CAA). I compared CAA participants to the normal population and cognitively similar patient populations, distinguishing between CAA syndromes, and determining whether white matter hyperintensity volume or the apolipoprotein ε4 allele mediate cognitive impairment. Cross-sectional data revealed lower performance on tests of perceptual speed, episodic memory, and executive functioning in CAA when compared to the normal population. Overall, CAA was most cognitively similar to vascular cognitive impairment. My research findings were presented at the International CAA Conference in London, England in 2014 and published in the journal Stroke in 2016. This research was supervised by Dr. Eric Smith. Funding was provided by the Canadian Stroke Network, Heart and Stroke Foundation of Alberta, Alzheimer Society of Canada, Alberta Innovates–Health Solutions, Canadian Institutes of Health Research, and Pfizer Cardiovascular research award.
2010Â - 2013
Bachelor of Arts - Psychology, University of Calgary
I conducted a mixed-methods research exploration of motivations for amends-making in romantic relationships. My research found that high narcissism and high growth beliefs together play a role in the emergence of empathy and the desire to be forgiven as motives for amends-making among transgressors. In revealing these motives for amends-making, my research broadens the overwhelmingly negative perceptions of narcissism. This research was conducted under the supervision of Dr. Susan Boon.
Experience Beyond Academia
2024 - present
Member -- Board of Directors, The Howl Experience
-
Contribute to strategy development for The Howl Experience, an Indigenous-led charity that offers land-based learning programs for youth
2023
Certificate: Project Management Professional, Project Management Institute
-
Extensive knowledge and mastery of project management concepts, tasks, and techniques that are applicable across virtually any industry and methodology
-
Knowledge and skills needed to initiate, plan, execute, monitor and control, and close a project
2022 - 2023
Impact Consulting Fellow, Propel Impact (formerly Social Innovation Academy)
-
Trained in social innovation research, design, and finance
-
Completed two 3-month consulting challenges in impact measurement and market research for social innovation organisations
2022
Alumna (2023-present) / Vice-curator (2022) / Member (2020 - 2022), Montreal Hub - Global Shapers Community
-
Led the writing of a whitepaper on tools of oppression and empowerment of Indigenous, Black, and Palestinian communities in Canadian education systems.
-
As vice-curator, I co-led the Montreal Hub of the World Economic Forum's Global Shapers Community, a network of young people driving dialogue, action and change.
-
Led the impact measurement, mixed-methods analysis, and reporting for our in-house Sustainable Development Goals (SDGs) alignment tool.
2022
One Young World Scholar, Johnson & Johnson
-
Completed project leadership course and two social impact challenges in the One Young World program
-
Led a team of 6 Johnson & Johnson employees to conduct research on social impact frameworks for clinical cardiovascular research
2021
Certificate: Canadian Private Capital Investment School,
Ivey Business School and the Canadian Venture Capital & Private Equity Association
-
Only applicant selected for merit-based full sponsorship from Amplitude Ventures
-
Trained in the future of investing, entrepreneurs' perspective, managing portfolio companies, investing in a time of turbulence, deal flow management, due diligence, legal & tax, negotiations, and valuation
2017 - 2022
Co-founder, Health Innovation Initiative
-
Created a Montreal-based non-profit organization to support growth in health innovation in Canada through collaboration
-
Hosted 900+ attendees at our educational and facilitated networking events
-
Provided pro-bono financial consulting to Protection Collective, a community of 3D-printing hobbyists who produced and donated nearly 3000 face shields to frontline healthcare workers in Montreal as part of the COVID-19 first-wave emergency response to shortages.
2013 - 2015
Clinical Rater, University of Calgary
-
Completed 7 certifications in experimental testing protocols, good clinical practice, and data management
-
Tested participants in Phase II clinical trials for Boehringer Ingelheim (BI-1289.6 Protocol) & EnVivo Pharmaceuticals (EVP-6124-015 Protocol) to identify cognitive changes as a result of experimental antipsychotics. This work was under the supervision of Dr. Thomas Raedler in the Psychopharmacology Research Unit.